265.52
Overview
News
Price History
Option Chain
Why AMGN Down?
Discussions
Forecast
Stock Split
Dividend History
AMGEN Inc. (AMGN) current stock price is $265.52 with a 24-hour trading volume of 1.75M.
The stock increased by +0.47% in the last 24 hours and rose by +1.51% in the past month.
Looking at the chart, AMGN stock price is above the pivot point level of $263.8, suggesting a potential bullish market, if it continues to reach close to the resistance level of $266.0, significant changes may happen.
Moreover, exploring the underlying reasons why AMGN is dropping is crucial for acquiring comprehensive view about the stock.
AMGEN Inc. (AMGN) stock has undergone a total of 5 stock splits since its initial public offering which has affected the stock’s price and liquidity.
AMGEN Inc. Stock (AMGN) Latest News
Is Trending Stock Amgen Inc. (AMGN) a Buy Now?
Zacks Investment Research
1 Spectacular Dividend Stock Every Investor Should Consider
The Motley Fool
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Zacks Investment Research
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Zacks Investment Research
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
Zacks Investment Research
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
MarketWatch
AMGEN Inc. Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
Earnings per Share
AMGEN Inc. Stock (AMGN) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Graham Jonathan P | EVP, Gen. Counsel & Secy. |
Nov 08 |
Sale |
272.81 |
10,000 |
2,728,136 |
28,078 |
AMGEN INC | 10% Owner |
Sep 19 |
Buy |
17.00 |
1,764,705 |
29,999,985 |
35,368,653 |
Gordon Murdo | EVP, Global Commercial Ops |
Aug 10 |
Sale |
262.43 |
9,558 |
2,508,306 |
44,308 |
About AMGEN Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center, and Provention Bio, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Cap:
|
Volume (24h):